Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.
- 1Department of Urology, Peninsula University Hospital, Bayside Health, Melbourne, VIC, Australia.
Abstract
Androgen deprivation therapy remains the cornerstone of systemic treatment for advanced prostate cancer. However, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. Supraphysiological androgen exposure can suppress tumor growth in selected biological contexts, a phenomenon termed the "testosterone paradox." Bipolar androgen therapy (BAT), which rapidly cycles between supraphysiological and near-castrate testosterone levels, has emerged as a novel strategy. This narrative review summarizes contemporary biological insights, clinical evidence, and evolving investigational treatment strategies for BAT in CRPC. A structured narrative literature search of Ovid MEDLINE and Embase (January 2009 to August 2025) was conducted. Chronic androgen suppression promotes adaptive androgen receptor (AR) upregulation, creating a potential vulnerability to supraphysiological androgen exposure through multiple mechanisms reviewed in this study. Clinically, BAT has been evaluated in multiple phase I-II studies involving more than 250 men with CRPC. In selected asymptomatic patients enrolled in early-phase studies, BAT demonstrated feasibility and manageable toxicity, with prostate-specific antigen and radiographic responses observed in approximately 25% to 30% of patients. To date, the most consistent clinical signal has been the restoration of sensitivity to subsequent AR pathway inhibition, along with improvements in selected health-related quality-of-life domains. Combination strategies involving AR inhibitors, poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and other targeted agents are under active investigation, supported by emerging biomarker-driven hypotheses. International guidelines currently classify BAT as investigational, because of the absence of phase III survival data. Bipolar androgen therapy challenges the conventional androgen suppression paradigms in CRPC and remains an investigational therapeutic strategy for CRPC.
Related
- A low-androgen environment sustains redox-active sGC states required to restrain castration-resistant prostate cancer growth via elevated cGMP levels
- Prediction models for progression to castration-resistant prostate cancer after androgen deprivation therapy: a narrative review (2021–2026)
- Interferon Therapy in Acute Myeloid Leukemia: Biological Rationale, Clinical Evidence, and Future Directions
- Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions
- An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation.
BibTeX
@article{rival2026bipolar,
title = {{Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.}},
author = {Paul M Rival and Jeffrey Jiang and Liang G Qu and Jonathan O'Brien and Paul Gilmore and Niall Corcoran},
journal = {Current urology},
year = {2026},
month = sep,
doi = {10.1097/cu9.0000000000000374},
url = {https://europepmc.org/article/MED/42960082},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Bipolar androgen therapy in castration-resistant prostate cancer: Biological rationale, clinical evidence, and future directions.
AU - Paul M Rival
AU - Jeffrey Jiang
AU - Liang G Qu
AU - Jonathan O'Brien
AU - Paul Gilmore
AU - Niall Corcoran
PY - 2026
DA - 2026/09/23
JO - Current urology
DO - 10.1097/cu9.0000000000000374
UR - https://europepmc.org/article/MED/42960082
AB - Androgen deprivation therapy remains the cornerstone of systemic treatment for advanced prostate cancer. However, progression to castration-resistant prostate cancer (CRPC) is almost inevitable. Supraphysiological androgen exposure can suppress tumor growth in selected biological contexts, a phenomenon termed the "testosterone paradox." Bipolar androgen therapy (BAT), which rapidly cycles between supraphysiological and near-castrate testosterone levels, has emerged as a novel strategy. This narrative review summarizes contemporary biological insights, clinical evidence, and evolving investigational treatment strategies for BAT in CRPC. A structured narrative literature search of Ovid MEDLINE and Embase (January 2009 to August 2025) was conducted. Chronic androgen suppression promotes adaptive androgen receptor (AR) upregulation, creating a potential vulnerability to supraphysiological androgen exposure through multiple mechanisms reviewed in this study. Clinically, BAT has been evaluated in multiple phase I-II studies involving more than 250 men with CRPC. In selected asymptomatic patients enrolled in early-phase studies, BAT demonstrated feasibility and manageable toxicity, with prostate-specific antigen and radiographic responses observed in approximately 25% to 30% of patients. To date, the most consistent clinical signal has been the restoration of sensitivity to subsequent AR pathway inhibition, along with improvements in selected health-related quality-of-life domains. Combination strategies involving AR inhibitors, poly(ADP-ribose) polymerase (PARP) inhibitors, immunotherapy, and other targeted agents are under active investigation, supported by emerging biomarker-driven hypotheses. International guidelines currently classify BAT as investigational, because of the absence of phase III survival data. Bipolar androgen therapy challenges the conventional androgen suppression paradigms in CRPC and remains an investigational therapeutic strategy for CRPC.
SN - 1661-7649
SN - 1661-7657
ER -